| 陆云南,许 红,冯志强,马 涛,何培成,吴双双,华 烨.恩必普联合依达拉奉治疗急性脑梗死的临床疗效及对血清高敏C反应蛋白的影响[J].现代生物医学进展英文版,2017,17(33):6514-6517. |
| 恩必普联合依达拉奉治疗急性脑梗死的临床疗效及对血清高敏C反应蛋白的影响 |
| Therapeutic Effect of Butylphthalideon Combined with Edaravone on the Patients with Acute Cerebral Infarction and Influence on the Serum hs-CRP |
| Received:May 12, 2017 Revised:June 06, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.33.026 |
| 中文关键词: 恩必普 依达拉奉 急性脑梗死 高敏C反应蛋白 |
| 英文关键词: Butylphthalide Edaravone Acute cerebral infarction hs-CRP |
| 基金项目:2015年江苏省干部保健科研课题(BJ15018) |
|
| Hits: 149 |
| Download times: 129 |
| 中文摘要: |
| 摘要 目的：观察恩必普联合依达拉奉治疗急性脑梗死的临床疗效及对血清高敏C反应蛋白(hs-CRP)的影响。方法：将78例急性脑梗死患者按随机分成两组，每组各39例，并给予两组患者常规的抗急性脑梗死治疗。对照组患者采用依达拉奉注射液治疗，静脉滴注，30 mg/次，2次/d，持续10 d。在此基础上，观察组患者采用恩必普(丁苯酞软胶囊)治疗，餐前口服，200 mg/次，3次/d，持续10 d。分别观察和比较两组患者的总有效率、治疗前后的NIHSS评分和血清hs-CRP水平的变化以及治疗过程中不良反应的发生情况。结果：观察组和对照组的总有效率分别为94.87%和79.49%，观察组的总有效率显著高于对照组(P<0.05)；两组患者治疗后的NIHSS评分和血清hs-CRP水平均较治疗前明显下降(P<0.05)，且观察组的NIHSS评分和血清hs-CRP水平明显低于对照组(P<0.05)；此外，两组患者均无严重不良反应发生(P>0.05)。结论：采用恩必普联合依达拉奉治疗急性脑梗死能明显改善神经功能缺损，降低血清hs-CRP水平，提高临床疗效，且无严重不良反应发生。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the therapeutic effect of butylphthalideon combined with edaravone on the patients with acute cerebral infarction and influence on the high sensitive C reaction protein (hs-CRP). Methods: 78 cases of patients with acute cerebral in- farction were randomly divided into two groups with 39 patients in each group. Patients in both groups were given conventional therapy of acute cerebral infarction. Patients in the control group were given edaravone intravenously, 30mg/time, twice one day, for 10 days. On the base of control group, patients in observation group were treated by butylphthalide soft capsules additionally before meals, 200mg/time, 3 times one day, for 10 days. Then the therapeutic effect, changes of NIHSS and hs-CRP before and after treatment as well as the incidence of adverse reactions were compared between two groups. Results: The total effective rate of observation group was 94.87%, which was significantly higher than that of the control group(79.49%, P<0.05). After treatment, the NIHSS and serum hs-CRP levels of both groups were obviously decreased than those before treatment(P<0.05), the NIHSS and hs-CRP of observation group were lower than those of the control group after treatment (P<0.05). No serious adverse reactions was found in both groups. Conclusion: Butylphthalide combined with edaravone could obviously improve the neurological deficit of patients with acute cerebral infarction, re- duce the hs-CRP level and enhance the therapeutic effect. |
|
View Full Text
View/Add Comment Download reader |
| Close |
